CBD has seen a huge spike in popularity recently. It’s being utilized by consumers who are seeking relief from a variety of ailments, including anxiety, stress, epilepsy, and so much more. If you didn’t know, CBD is short for cannabidiol, one of the many cannabinoids that make up the hemp plant, and it is legal in all 50 states. Here are some of the most revolutionary clinical trials that may back up some of the health claims consumers have been experiencing after trying this supplement:
- Clinical Trials on CBD and Cancer
- Clinical Trials on CBD and Pain
- Clinical Trials on CBD and Sleep
- Clinical Trials on CBD and Colitis and Other Digestive Issues
- Clinical Trials on CBD and Migraines
- Clinical Trials on CBD and Epilepsy
- Clinical Trials on CBD and Psychiatric Conditions
- Clinical Trials on CBD and Weight Loss
1. CBD has been shown to be effective in pre-clinical models of breast cancer. A 2010 pre-clinical study found that CBD may inhibit breast cancer cell proliferation and metastization. More studies need to be done on cannabinoids and cancer progression.
2. Cannabinoids could be promising for the treatment of gliomas. After looking at 35 clinical studies, a 2014 review in the Journal of Neuro-Oncology found that cannabinoids showed antitumoral effects in multiple tumor models. These findings show that the treatment of gliomas with cannabinoids may be promising in the future.
3. CBD may inhibit colon cancer. A 2014 study found that CBD may reduce colon carcinogenesis and inhibit cancer cell proliferation. The study points to both CB1 and CB2 receptor activation as the potential mechanism for this effect.
4. CBD may be effective in treating brain cancer. A 2017 study found that CBD enhanced the effects of radiation glioblastoma. This may allow for less use of radiation and, therefore, fewer severe side effects.
5. Cannabidiol may induce cell death of glioblastoma. Another study in 2019 looked at CBD’s effects on glioblastoma. In this study, researchers found that cannabidiol can induce cell death and enhance the sensitivity of the cancer to radiation.
6. Cannabinoids may be an effective treatment for pancreatic cancer. A 2019 review found that CBD may provide treatment for pancreatic cancer, especially in connection with radiation. The review concluded that more clinical studies are needed.
7. Cannabidiol may reduce chronic inflammation and neuropathic pain. A 2007 report published in the European Journal of Pharmacology investigated the potential of CBD on neuropathic and inflammatory pain in rats. The results indicate a potential for therapeutic use of CBD in chronically painful states.
8. Chronic pain patients prefer cannabis to prescription opioids. Researchers for a 2018 article in the Journal of Headache and Pain investigated the use of medical cannabis and prescription drugs in over 2,000 patients licensed to access marijuana products. Among those patients with a diagnosis of chronic pain, 73 percent reported substituting cannabis in place of opioids.
9. Cannabidiol was found to inhibit neuropathic pain in connection with chemotherapy. A 2014 study found that CBD may have protective effects against neurotoxicity caused by chemotherapy through the 5-HT(1A) receptor system. Additionally, CBD treatment did not affect the results of the chemotherapy on cancer cells in this study.
10. Cannabinoids may be effective in treating neuropathic pain experienced by those with MS. A 2007 review summarized the efficacy and safety of cannabinoid for neuropathic pain in patients with multiple sclerosis (MS) based on 18 articles and three randomized controlled trials. It concluded that, for some patients in the studies analyzed in this review, cannabinoids were superior to placebo in treating pain caused by MS.
11. Cannabis may reduce pain to help patients with chronic pain sleep. A 2007 review found marked improvement in sleep in patients with a wide variety of pain conditions including MS, neuropathic pain, cancer pain, and rheumatoid arthritis. This may contribute to improved quality of life in chronic pain patients.
12. Cannabinoids have been shown to be effective in treating neuropathic pain models. A 2014 review in the Current Pain and Headaches Report explored the evidence for therapeutic use in human neuropathic pain conditions. It concluded that cannabinoids may be effective for treating pain and more studies need to be completed.
13. In a 2007 study, CBD was found to be effective in treating pain with no evidence of tolerance. In a randomized trial performed on 66 patients, a 2007 study found that CBD was effective in treating pain in patients with CNP and MS. Even better, the patients in this study showed no signs of building up a tolerance to the CBD, which is a common side effect of typical pain medication.
14. CBD may be effective in treating neuropathic orofacial pain (NOP). A 2014 review looked at the effect of CBD on facial pain, including burning mouth syndrome, among others. The review found that CBD may show promise for future therapeutic treatment options for NOP.
15. Cannabidiol may help to treat pain caused by acute inflammation. In a 2004 study on rats, researchers found that transient receptor potential vanilloid type 1 (TRPV1) could be the molecular target that CBD reacts with to cause pain relief. This study helps scientists better understand how CBD may treat pain caused by acute inflammation.
16. Cannabidiol was shown to relieve incision pain in rats. A 2017 study in Frontiers of Pharmacology examined the effects of CBD on the relief of incision pain. The study gives further support to the idea that the different dimensions of pain may be differently relieved by CBD.
17. CBD may relieve even difficult to treat pain. A 2008 review concluded that cannabinoid pain relievers are well tolerated and don’t produce any significant negative side effects. Their addition to the pharmacological treatment for pain needs to be explored further, but it may show promise for future potential uses.
18. CBD was found to increase total sleep time. Based on a study on adult male Wistar rats, a 2014 study found that total sleep time significantly increased in the groups treated with CBD compared to the placebo. REM sleep latency was also increased as well.
19. CBD was found to modulate sleep in rats. A 2009 study found that cannabidiol induces alertness. Therefore, researchers concluded that it might be of therapeutic use to help people with sleep disorders, such as excessive daytime sleepiness.
20. Cannabidiol oil may have helped a childhood case of insomnia. A case study published in The Permanente Journal in 2016 found that cannabidiol oil decreased anxiety and helped improve the quality and quantity of sleep in a young girl. This case study provides clinical data that support the potential use of CBD oil as a safe treatment for sleep and anxiety.
21. Endocannabinoid signaling may help to regulate sleep. Based on series of experiments in mice, a 2016 study found that the endocannabinoid system regulates sleep patterns. Since CBD directly impacts the endocannabinoid system, this may explain why some consumers have found relief from many sleep disorders.
22. The endocannabinoid system helps regulate non-REM sleep. Another study on the endocannabinoid system in 2014 studied the effect of the endocannabinoid system and up and down state transitions during non-REM sleep. It found that this system regulates features of non-REM, including its duration and frequency.
23. Cannabinoids may provide treatment for colonic inflammation. A 2012 study found that treatment of mice with CBD led to improvement of colonic inflammation. Researchers concluded that CBD may prove to be a useful therapeutic treatment for colitis.
24. Cannabis has been shown to have therapeutic potential in the treatment of gut issues. A 2010 review looked at how the endocannabinoid system impacts the gut in health and disease. It focused on the pharmacological actions of cannabinoids and their treatment potential in relation to GI disorders.
25. Further research is needed to develop therapeutics to target inflammatory bowel disease. Another review published in 2017 looked at the manipulation of the endocannabinoid system when it comes to colitis. It determined that although cannabinoids have been proven to reduce inflammation, further research is needed on human subjects before clinical treatments can be developed.
26. Cannabidiol may reduce intestinal inflammation through the neuroimmune axis. A 2011 study investigated the effect of CBD on intestinal biopsies from patients with ulcerative colitis. It found that, in patients participating in this study, cannabidiol reduced inflammation through control of the neuroimmune axis.
27. Cannabigerol has been shown to have a possible beneficial effect on inflammatory bowel disease. A 2013 study published in Biochemical Pharmacology investigated the effect of cannabigerol, a cannabis-derived cannabinoid present in full-spectrum CBD, on colitis. It found that CBG reduced the colitis and its effects among patients participating in this study.
28. The endocannabinoid system may play a big role in the brain-gut axis. A 2016 review investigated how the endocannabinoid system effects the brain-gut axis. It concluded that increasing our understanding of the ECS will advance our knowledge of how the brain and gut interact and may lead to new treatments for gastrointestinal disorders.
29. The endocannabinoid system may protect the GI tract. A 2006 review published in the Journal of Endocrinological Investigation concluded that the ECS may protect the GI tract from inflammation and abnormally high gastric and enteric secretion. Therefore, the endocannabinoid system may hold the key in developing new treatments for Crohn’s disease, irritable bowel syndrome, and so much more.
30. CBD may be as effective in preventing migraines as medication. A study presented at the Congress of the European Academy of Neurology in Amsterdam concluded that cannabinoids may work just as well in preventing migraine attacks as pharmaceutical treatments. It also concluded they were not as effective in treating acute cluster headaches unless the patient had previously suffered with migraines.
31. Medical marijuana has been shown to prevent migraines. A study performed between 2015 and 2016 on 121 adults found that the frequency of migraine headaches decreased with medical marijuana use. Researchers concluded that more research should be conducted to explore a cause‐and‐effect relationship and the use of different formulations and doses to better understand the connection.
32. Cannabidiol may be a treatment option for childhood epilepsy. A 2017 review looked at a series of studies that show that CBD may have efficacy for treatment of epilepsy. Researchers concluded that double-blind, controlled trials are needed, along with the potential use of CBD to treat other neurological problems.
33. Cannabidiol may be effective in treating seizures in those with Sturge-Weber syndrome. A 2017 study suggests that cannabidiol may be effective for seizure management in individuals with Sturge-Weber syndrome. Researchers found that it was well-tolerated with minimal side effects for participants in this study.
34. CBD may provide protective effects against seizures and neuronal death. In a 2017 study on rats, it was found that the anticonvulsant and neuroprotective effects of CBD may act as preventive treatment for epilepsy. Researchers concluded that the study reinforces the potential role of CBD in the treatment of epilepsy.
35. The endocannabinoid system plays a pivotal role in epilepsy. A 2017 review looked into newly-identified targets and indications signaling in epilepsy. It found that the CB1 receptor exerts anti-convulsant effects and that CBD exerts anti-seizure and anti-epileptogenic properties.
36. More research on cannabinoids as a treatment for epilepsy needs to be completed. Another 2017 review looked at the available scientific data from human and animal studies on cannabinoids as a treatment of epilepsy. It concluded that more research needs to be completed regarding optimal drug delivery and potential drug interactions.
37. Data supports that CBD may have potential fast-acting antidepressant drug. A 2019 study looked at whether CBD could induce rapid and sustained antidepressant effects. Results showed that, for participants in this study, a single dose of CBD induced antidepressant-like effect.
38. CBD may act as an antidepressant and anti-anxiety agent. A 2014 review looked at studies of animal models using CBD as an anti-anxiety treatment and antidepressant. The review found that studies were promising for both disorders.
39. CBD may have anti-anxiety, antipsychotic and neuroprotective properties. A 2009 review published in Frontiers in Immunology looked at the main advances in the use of CBD in neuropsychiatry. They concluded that CBD may have anti-anxiety, antipsychotic and neuroprotective properties.
40. Cannabidiol may be used as an alternative to antipsychotics. Because antipsychotics have severe side effects, a 2016 review looked at the antipsychotic effects of CBD. The review concluded that CBD exhibits potent antipsychotic properties with far fewer side effects.
41. CBD may help those with a fear of public speaking. A 2018 study found that treatment with 300 mg of CBD experienced reduced anxiety during a speech. Researchers conclude that an acute dose of CBD may be effective for decreasing anxiety.
42. CBD may reduce social anxiety disorder. A 2010 study investigated patients with generalized social anxiety disorder (SAD) using neuroimaging. The findings suggest that CBD may reduce anxiety in SAD due to its effects on the limbic and paralimbic brain area.
43. CBD may relieve anxiety with minimal side effects. A 2015 review concluded that preclinical evidence demonstrates CBD’s potential effectiveness in reducing anxiety from a multitude of disorders, including PTSD, OCD, and SAD. It noted that more research needs to be done into the mechanisms and receptor actions of CBD.
44. CBD may provide relief to those suffering with PTSD. A 2018 review showed that CBD may offer therapeutic benefits for PTSD. It shows promising effects on aversive memory processing with little to no side effects as opposed to typical pharmacological therapy.
45. More researched on CBD in psychiatry is needed. After studying six case reports and seven trials, a 2019 review concluded that the evidence backing up the effectiveness of CBD in psychiatry is still scarce. Further well-designed, controlled trials are needed.
46. Cannabidiol may reduce appetite. A 2012 study found that cannabidiol (CBD) and cannabinol (CBN) exerted different effects on the feeding patterns in mice. CBD reduced total chow consumption, while CBN significantly increased the intake.
47. Cannabinoids target the CB1 molecule to regulate feeding behavior. A 2017 review found that cannabinoid receptor type 1 (CB1) represents the most relevant target molecule of cannabinoids. This receptor plays a large role in regulating feeding behavior.
48. Cannabidiol may promote brown fat. Increasing the amount of brown fat in the body has been shown to help prevent and treat obesity. A 2016 study found that CBD may promote the browning of white fat cells.
49. The risk of obesity has been found to be lower in cannabis users. A 2011 review looked at 2 representative epidemiologic studies of U.S. adults to estimate the prevalence of obesity in cannabis and non-cannabis users. They found that the prevalence of obesity is lower in cannabis users than in non-users.
50. Marijuana use appears to be associated with a lower body mass index. A 2014 paper published in Innovations in Clinical Neuroscience found that marijuana may increase weight in those who are underweight, but not in those who are normal or overweight. It also found that those who use marijuana long term tend to have a lower BMI than non-users, on average.
The clinical studies that focus on CBD are only in their infancy, and we expect to see countless future developments in the coming months and years. If you’re looking to give hemp a try, check out our proprietary full-spectrum Hemp Extract powder. It’s completely tasteless and dissolves in any food.